Cinnarizine Tables:
Pharmacokinetics
Bioavailability
Peak plasma level
Plasma half-life
Active metabolites
Elimination
high variability
not established
2 to 3 hours
4 to 6 hours
not established
predominantly extrarenal
Probably polymorphically determined "debrisoquine" metabolism. The pharmacokinetics of cinnarizine in humans is only incompletely documented.
Dose
Indication
Administration
Initial loading dose
Dose
Interval
Maintenance dose
Dose*
Interval
motion sickness
oral
12.5 to 25 mg**
8 to 12 hours
-
-
labyrinthine vertigo
oral
25 mg
8 to 24 hours
25 mg
8 to 24 hours
*Considering the possible side-effects, a long-term administration is not advisable; high doses (more than 75 mg/day) should be avoided in particular.
**The first dose should be taken one or two hours before traveling.
Copyright © 1996 Infomed-Verlags AG